Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BJHL Biotech, Inc. 〉JHL1266 Denosumab Biosimilar

JHL1266 Denosumab Biosimilar

JHL1266 Denosumab Biosimilar

A fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL)

Request for Collaboration
Overview
JHL1266 is a proposed biosimilar to denosumab, which is a monoclonal antibody used for treatment of a range of osteoporosis.
Application
Osteoporosis, Bone Cancer, Bone Loss, Bone pain, Fracture Bone, Spinal Cord Compression, Bone destruction, Giant cell tumor of the bone, High risk of fracture, Refractory Hypercalcemia of malignancy
People who like this also like
  • Homogeneous antibody drugs (CHO-H01, H02, H03)Homogeneous antibody drugs (CHO-H01, H02, H03)
  • PHDC-01PHDC-01
  • Applying next generation sequencing in preimplantation genetic screeningApplying next generation sequencing in preimplantation genetic screening
  • PDL(Precision Dimension Laser)PDL(Precision Dimension Laser)
  • RNTA06RNTA06
  • Complete and Comprehensive Design/Production CapabilitiesComplete and Comprehensive Design/Production Capabilities
  • CX-5461: RNA Polymerase I (Pol I) Inhibitor ProgramCX-5461: RNA Polymerase I (Pol I) Inhibitor Program
  • TAT-HOXB4TAT-HOXB4
  • CRAM ServicesCRAM Services
  • Zelnite®Zelnite®